|
Monday 8th December 2025 |
Text too small? |
Rua Bioscience is pleased to provide an update on the progress of its pro rata rights offer currently open to eligible shareholders.
To date the Company has received commitments for over $1.5 million from existing shareholders, with a total of $2 million on offer. This demonstrates strong support for Rua’s strategy and the objectives of the capital raise. These commitments reflect the confidence of shareholders in the Company’s commercial progress, operational execution, and long-term growth ambitions in the global medicinal cannabis sector.
The pro rata rights offer remains open until the end of day on Friday, 12 December 2025. Any shareholder that wishes to participate should do so before this date. Full details of the offer, including the timetable and instructions on how to take up rights, are set out in the Offer Document available at www.ruabio.com/capital-raise-november-2025.
Funds raised through the Rights Offer will be applied to working capital and marketing activities to support Rua’s growth opportunities, including the launch and commercialisation of new products across key international markets such as Germany, Australia, the United Kingdom, and Czechia.
ENDS
No comments yet
CHI - Channel Infrastructure delivers solid FY25 financial result
February 27th Morning Report
TRU - Results Guidance FY2026
TRU - Results Guidance FY2026
MEE - Me Today announces six-month results to 31 December 2025
HGH - Heartland announces 1H2026 result
BRW - FY26 Half Year Results Announcement
February 25th Morning Report
Genesis completes NZ$100m Placement
MCY - Invests heavily in renewables; delivers strong performance